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Exhaled breath condensate (EBC) contains extracellular DNA that may originate from patholog-
ical lesions of the respiratory tract and can be a genetic marker of pulmonary malignancy. We
tested whether complete surgical excision of lung cancer will decrease exhalation of mutated
KRAS oncogene.
Fifty seven patients with clinical diagnosis of lung cancer and detectable KRAS mutations in
pre-surgery EBC-DNA were qualified for surgical treatment. Point mutations at codon 12 of
KRAS oncogene were detected using mutant-enriched PCR technique in DNA from pre-
surgery blood, EBC collected before, 7 and 30 days after surgery and from specimens of re-
sected tumor and normal pulmonary parenchyma. The ratio of mutated to wild type KRAS
DNA (R mut/wild KRAS) was calculated for each specimen after electrophoresis and densitom-
etry of the final amplification and digestion product.
In 46 patients non-small cell lung cancer (NSCLC) and in 11 benign lesion (BL) were
confirmed. All blood and tumor specimens were positive for KRAS mutations, while 41 speci-
mens of normal pulmonary parenchyma were negative. In NSCLC patients pre-surgery EBC R
mut/wild KRAS of 0.20  0.03 decreased by 1.3- and 3.7-times (p < 0.001) at 7th and 30th
day and 10 EBC specimens at day 30th became negative. The highest R mut/wild KRAS was
found in NSCLC specimens e 1.36  0.29 while the lowest in pulmonary parenchyma e
0.02  0.03 (p < 0.001). R mut/wild KRAS in EBC did not correlate with the blood and cancer
ratios.48 426781800.
ed.lodz.pl (D. Nowak).
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Analysis of exhaled biomarkers including various alkanes
and their derivatives, reactive oxygen species, or DNA
fragments could potentially be useful in detection of lung
cancer.1e5 These biomarkers can be monitored directly in
exhaled air with combination of gas chromatography and
mass spectrometry technique4,5 or with electronic nose
device that consists of nanosensors based on organically
functionalized gold nanoparticles.3 Another approach to
detection of pulmonary malignancy is collection of exhaled
breath condensate (EBC) and its further analysis with
various variants of PCR technique.6,7
EBC collection seems to be a promising, non-invasive
tool for evaluation of various lung disorders.1,2,8,9 EBC
consists of condensed water vapor, other volatile compo-
nents and droplets generated within airways that contain
numerous non-volatile compounds including human
DNA.1,2,6,8,9 Although these droplets constitute less than
a few percents of EBC volume,8 application of sensitive
molecular methods made possible to detect genomic
alterations in lung cancer patients.6 DNA extracted from
EBC (EBC-DNA) of patients with non-small cell lung cancer
(NSCLC) revealed mutations of p53 gene,7 alterations of
microsatellite DNA of chromosomal region 3p and 19q10,11
and methylation of selected gene promoters.12 Moreover,
the number of 3p microsatellite alterations of EBC-DNA
correlated with survival of NSCLC patients13 and was asso-
ciated with cigarette smoking.14 Therefore, serial analysis
of EBC-DNA, feasible even in severely ill subjects could be
a valuable diagnostic and prognostic tool.1
Mutations in the KRAS oncogene are implicated in the
development of malignancy including lung cancer.15
Majority of KRAS mutations was detected at codon 12 of
the KRAS gene.16 They occur frequently in the adenocar-
cinoma of the lung and to a lesser extent in squamous cell
carcinoma.15 DNA isolated from sputum and bron-
choalveolar lavage fluid (BAL) of lung cancer patients dis-
closed the KRAS abnormalities.17e19 Therefore, at least
part of EBC specimens obtained from patients with lung
cancer should contain mutant KRAS DNA. Tumors from
NSCLC patients treated with preoperative chemotherapy
had almost 3-times lower prevalence of mutated KRAS
oncogene than tumors from patients submitted to surgery
alone.20 In addition, stool DNA abnormalities (including
KRAS mutations) disappeared almost completely after 6e9
months from resection of colorectal carcinoma.21
Considering lung cancer as a source of mutated EBC-
DNA, we speculate that EBC specimens positive for KRAS
mutations may become negative after removal of pulmo-
nary malignancy. Therefore, we decided to select the group
of patients with lung malignancy positive for KRAS mutation
in EBC-DNA and then, to evaluate the effect of complete
tumor resection on the ratio of mutant to wild type KRAS
oncogene (R mut/wild KRAS) in EBC and to correlate this
ratio with selected clinical variables.Material and methods
Study population
The study, conducted from March 2007 to January 2011,
involved 57 patients with clinical diagnosis of lung cancer
qualified for complete tumor resection at the Department
of Chest, Oncologic and General Surgery, University
Hospital No. 2, with detectable KRAS mutations at codon 12
in EBC-DNA. This group was selected from the 134 lung
tumor patients screened for KRAS mutations in EBC-DNA.
The exclusion criteria included any history of other malig-
nancy, any treatment (e.g. radiotherapy, chemotherapy)
that might induce gene mutations before the enrollment;
any active infectious disease and the need for post-
operative mechanical ventilation. All patients underwent
standard diagnostic and staging procedures that involved
chest X-ray, computed tomography of the chest, abdomen
and brain, radionuclide bone scan, bronchoscopy and/or
transthoracic biopsy.
Overall, in 46 patients NSCLC and in 11 benign lesion (BL)
were diagnosed according to histological examination of
resected tumor (Table 1). NSCLC group involved 22 patients
with squamous cell carcinoma, 17 with adenocarcinoma, 4
with bronchioloalveolar carcinoma and 3 patients with
large cell undifferentiated carcinoma. Patients with benign
lesion had hamartoma  3, focal fibrosis  3, tuberculmoa
 2, carcinoid  1, focus of carnification  1, and hae-
mangioma sclerosans  1. The post-surgery NSCLC patients
classification was : stage IA e 11, IB -13, IIA-1, IIB e 13, IIIA-
6, and stage IIIB-2 subjects, respectively.
Characteristics of 61 patients with NSCLC (squamous cell
carcinoma  43, adenocarcinoma  17, large cell undif-
ferentiated carcinoma  1) and 9 with BL (hamartoma  2,
focal fibrosis e 4, tuberculoma  1 and carcinoid  2)
negative for pre-surgery KRAS mutations in EBC DNA and not
included in the study are shown in Table 1. As a control
served EBC-DNA from 52 patients (Table 1) admitted due to
planned surgical treatment of inguinal hernia (n Z 24),
crural varices (n Z 8), and gall stones (n Z 20). They did
not suffer from any chronic lung disease and malignancy in
the past.Study protocol
EBC was collected 3 times (within three days before and 7
and 30 days after surgery) in the study group, while in the
control only once before surgery. Along with the first EBC
a blood specimen (3 ml, EDTA-tubes) was collected for KRAS
analysis only in the study group. During the surgery about
1 g of cancer tissue and normal lung parenchyma were
collected and evaluated histologically. Samples of cancer
tissue were harvested at the peripheral part of the tumor
without signs of necrosis. The lung parenchyma was
collected as distant as possible from the tumor with the
Table 1 Characteristics of patients with non small cell lung cancer (NSCLC) and patients with benign pulmonary lesion (BL)
positive and negative for KRAS mutation in DNA extracted from exhaled breath condensate (EBC) before surgery and control
subjects without lung pathology.
Demographic/clinical
parameter
Patients positive for KRAS
mutations in EBC DNA
Patients negative for KRAS
mutations in EBC DNA
Control subjects
NSCLC BL NSCLC BL
Number 46 11 61 9 52
Sex F/M 12/34 4/7 17/44 4/5 15/37
Age (years) 64  10 56  8 66  7 58  6 58  9
Location P/C 24/22 11/0 29/32 9/0 NA
Surgery Pn/Bl/Lo/Wr 12/2/27/5 0/0/2/9 18/5/34/4 0/0/1/8 NA
Smokers/non-smokers 38/8 6/5 52/9 4/5 47/5
Pack-yearsa 42  27 32  21 37  19 28  9 36  17
134 patients with clinical diagnosis of lung cancer were screened for presence of KRAS mutations at codon 12 in EBC DNA. Only patients
positive for KRAS mutations in EBC DNA were included in the study. Seven patients that had small cell lung cancer (3 of them were
positive for KRAS mutations) were excluded from the study due to limited number making statistical analysis unfeasible. P e peripheral
(subpleural) location, C e central (hilar or peri-hilar location), Pn e pneumonectomy, Bl e bilobectomy, Lo e lobectomy, Wr e wedge
resection, NA e not applicable.
a Cumulative cigarette consumption e calculated only for cigarette smokers; data presented as mean and standard deviation, where
applicable.
Lung tumor and exhalation of mutated KRAS oncogene 1295separate set of surgical instruments. Tissue samples were
washed in ice-cold sterile 0.9% NaCl, desiccated with lignin
and frozen. The Ethics Committee of Medical University of
Lodz approved the study protocol and all participants
provided a written, informed consent. All specimens were
stored at 80 C for no longer than 30 days until analysis.
Collection of exhaled breath condensate
EBC samples (3e4 ml) were collected during 25 min of
spontaneous tidal volume breathing using EcoScreen-1
(Erich Jaeger GmbH, Hoechberg, Germany) with saliva
trap. The collecting temperature of the condenser was
20 C. Subjects wore a noseclip and rinsed their mouth
with distilled water (100 ml) just before and after 7 and
14 min of collection procedure to prevent EBC contamina-
tion with saliva and droplets of secretions of the nasal
mucosa. Each EBC specimens were also tested for amylase
levels (marker of salivary contamination) as previously
described.22 In all tested samples, no amylase was detec-
ted. All collections were done between 8:30 and 10:30 a.m.
and EBC specimens were immediately transferred to
Eppendorf tubes and frozen.
Postoperative management
All patients received second or third generation cephalo-
sporin for 2 weeks, low molecular weight heparin, and
fluids infusions depending on indications. Morphine, tra-
madol or metamizole were used to relieve postoperative
pain. No patient received blood or blood products
transfusion.
DNA extraction and detection of KRAS oncogene
point mutations
KRAS oncogene mutations (single point mutations) occur
mostly (80e90%) at codon 12.Other mutations at codon 13 and 61 are relatively rare
(less than 10%).23 Therefore, in this study we decided to
detect only mutations at codon 12. DNA was extracted from
blood specimens (0.3 ml), tumor tissue (1 g), pulmonary
parenchyma (1 g) and EBC (3 ml) according to the guani-
dium thiocyanate method.24 Isolated DNA was dissolved in
low TE buffer (5 mM Tris, 0.5 mM EDTA, pH Z 8.0) to final
concentration 25 ng/ml and stored at 20 C until assay.
Point mutations at codon 12 of KRAS oncogene were
detected using mutant-enriched PCR (MEPCR) technique.25
Briefly, 2 ml of isolated DNA solution (50 ng) were
added to 23 ml of reaction solution containing PCR GoTaq
polymerase buffer, 1.5 mM MgCI2, 0.08 mM dNTPs, 2 U Pfu
DNA polymerase (Promega Corp Madisom WI USA)
and 0.1 mM of the primers KRAS 3F (5
0
-ACTGAATA-
TAAACTTGTGGTAGTTGGACCT-30) and KRAS 10B (5
0
-ACT-
CATGAA AATGGTCAGAGAAACCTTTAT-30). PCR was carried
out using Biometra thermal cycler with an initial pre-PCR
heat step at 95 C for 5 min for polymerase activation,
followed by 20 cycles of 95 C for 30 s, annealing at 60 C
for 30 s and extension at 72 C for 30 s. This was followed
by a final step at 72 C for 10 min. Subsequently, 8 ml of
the PCR product was transferred to a new test tube
containing NEBuffer 2, bovine serum albumin (200 mg/ml),
2 U BstNI restriction enzyme (New England BioLabs, Bev-
erly, MA, USA) and incubated at 60 C overnight. Then 4 ml
of restriction digest was amplified in a second PCR run in
a final volume of 25 ml with PCR Gold Taq buffer, 1.5 mM
MgCI2, 200 mM dNTPs, 2 U Pfu DNA polymerase (Promega
Corp Madisom WI USA) and 0.5 mM of the primers KRAS 3F
and KRAS 14B (50-TCAAAGAATGGTCCTGGACC-30). PCR was
cycled at 95 C for 5 min, followed by 40 cycles of 95 C
for 30 s, annealing at 60 C for 30 s, extension at 72 C for
30 s and final extension at 72 C for 10 min. Amplified
product (15 ml) was digested a second time with 5 U BstNI
at 60 C overnight. The final digestion product was elec-
trophoresed on a 6% non-denaturing polyacrylamide gel
and 3% agarose gel, then stained with ethidium bromide
and visualized by UV transillumination. Mutant KRAS DNA
1296 J. Kordiak et al.was evident on the gel as single band of length 142 bp,
failure of digestion was evident as a band at 157 bp and
cleaved non-mutated (wild type) KRAS DNA was evident as
a band at 113 bp (Fig. 1A and B). When the band at 157 bp
was visible the result was rejected and all MEPCR steps
were repeated again. Wild type and mutated bands on
polyacrylamide gel were quantified by densitometry using
Image Master VDS gel documentation system (Pharmacia
Biotech). Images taken at the same magnification were
quantified by densitometry, on the basis of their contour
quantity after background subtraction and expressed in
arbitrary densitometry units using the Image Master VDS
software. The sensitivity of DNA detection with Image
Master was 76 pg of DNA per band and allowed to analyze
barely visible bands quantitatively.26
Then the ratio of mutated to wild type KRAS DNA (R mut/
wild KRAS) was calculated. Individual results were obtained
as themean from three separate runs of MEPCR. All PCR runs
included DNA-free PCR mix e negative control and DNA
prepared from the sequenced DNA isolated from lung cancer
(homozygous for the codon 12 KRAS valine mutation, GTT) -
positive control. EBC-DNA from the control group was
analyzed parallel to specimens from lung cancer patients.
Sequence analysis of KRAS oncogene mutations
Sequenceanalysis of DNA isolated frompulmonary lesionswas
performed by amplifying KRAS exon 2 by use of the following
primers: KRAS 17F (50-TGGTGGAGTATTTGATAGTGTA-30),Figure 1 Electrophoresis of the products of mutant-enriched
PCR technique of DNA extracted from specimens of resected
tumor, peripheral pulmonary parenchyma, exhaled breath
condensate (EBC) and blood obtained from A - 52 years old man
with adenocarcinoma of the lung (stage IIIa, central tumor
location, pneumonectomy) and B - 65 years old man with
squamous cell cancer of the lung (stage IIIA, central tumor
location, pneumonectomy). (A): 6% polyacrylamide gel; 1 - DNA
marker (Fermentas Life Sciences - GeneRuler 50bp ladder); 2 -
adenocarcinoma; 3 - peripheral pulmonary parenchyma; 4 -
pre-surgery blood; 5 -, 7 - pre-surgery EBC; 6 -, 8 - EBC 7 days
after surgery; 9 - EBC 30 days after surgery; 10 - DNA-free PCR
mix (negative control). (B): 3% agarose gel; 1 - peripheral
pulmonary parenchyma; 2 e squamous cell cancer; 3 e pre-
surgery blood; 4 - wild type KRAS DNA of 113 bp length; 5 -
mutant KRAS DNA of 142 length (point mutation: ggt/gct); 6
e pre-surgery EBC. Control KRAS DNA fragments (wild type and
mutant) were obtained by prior isolation of PCR products of the
length of 113 bp and 142 bp from 3% agarose gel, cloning in
TOPO TA vector (Invitrogen Carlsbad CA USA) and sequencing.KRAS 18B (50-CATGAAAATGGTCAGAGAA-30). The PCR products
were purified to eliminate unincorporated primers and dNTPs
and sequenced in Sequencing Service of Institute of
Biochemistry and Biophysics in Warsaw.
Statistical analysis
Results were expressed as mean  standard deviation or
median (quartile range) depending on the distribution
(tested formally with ShapiroeWilk W test). Between group
testing (NSCLC vs. BL) was done with Student t test or U-
ManneWhitney test. Within group testing (R mut/wild KRAS
in EBC at different time points) was done with Friedman
ANOVA and Wilcoxon test was used for comparisons at 2
different time-points. Chi-square test was applied for
testing the distribution of point mutations of KRAS onco-
gene in tumor DNA within study groups.
KruskalleWallis test was used for comparison of EBC R
mut/wild KRAS in NSCLC patients with stage I, II and III.
Correlations between R mut/wild KRAS in DNA from EBC,
blood and tumor tissue as well as associations of these with
selected clinical variables were determined using Pearson’s
r. Spearman’s r was used for analysis of correlations
between EBC R mut/wild KRAS and NSCLC patients stage.
A p value <0.05 was considered significant.
Results
KRAS mutations in EBC and blood before surgery
NSCLC patients had higher pre-surgery EBC R mut/wild
KRAS than those with BL (p < 0.05, Table 2). There were no
differences between EBC R mut/wild KRAS in NSCLC
patients with central and peripheral tumor (0.19  0.03 vs.
0.20  0.04, p Z 0.9) as well as squamous cell and other
NSCLC types (0.20  0.03 vs. 0.19  0.04, p Z 0.4).
EBC R mut/wild KRAS did not differ in subgroups of
NSCLC patients with various stages (p Z 0.4). Median
(quartile range) for NSCLC patients with stage III, II and I
were 0.18 (0.16e0.21, n Z 8), 0.20 (0.18e0.23, n Z 14)
and 0.20 (0.18e0.22, n Z 24), respectively.
Half of 52 control subjects had no detectable KRAS
mutation in EBC-DNA. The remaining subjects presented
with mutated KRAS, but individual EBC R mut/wild KRAS did
not exceed 0.09. Overall for this group mean  SD and
median (quartile range) of EBC R mut/wild KRAS was
0.028  0.032 and 0.002 (0.000e0.050), respectively.
All pre-surgery blood specimens were positive for KRAS
mutation. Blood R mut/wild KRAS reached similar values in
subjects with NSCLC and BL (Table 2). Staging (III vs. <III),
locus (central vs. peripheral) and histology (squamous cell
cancer vs. other types) did not affect blood R mut/wild
KRAS in NSCLC patients, data not shown.
KRAS mutations in tumor and matched pulmonary
parenchyma
All resected tumors were positive for KRAS mutation. In
NSCLC the higher R mut/wild KRAS was observed than in BL
(p Z 0.008, Table 2). NSCLC specimens from patients with
Table 2 Ratio of mutant to wild KRAS oncogene (R mut/wild KRAS) in patients with NSCLC and BL.
Source of isolated DNA Ratio of mutant to wild KRAS oncogene in patients with
NSCLC BL
EBC 0.20  0.03 (0.20; 0.17e0.23) 0.17  0.03 (0.17; 0.15e0.18)a
Blood 0.43  0.13 (0.46, 0.39e0.52) 0.36  0.19 (0.42, 0.32e0.50)
Tumor 1.36  0.29 (1.33; 1.18e1.62)b 1.09  0.27 (0.95, 0.88e1.32)a,b
Lung parenchyma 0.02  0.03 (0.00, 0.00e0.03)c 0.01  0.03 (0.00, 0.00e0.04)c
EBC (exhaled breath condensate) and blood were collected within 3 days before surgery. Tumor and lung parenchyma specimens were
obtained during complete surgical tumor resection. Results are expressed as mean and standard deviation and in parentheses as median
and quartile range.
a p < 0.05 vs. NSCLC.
b p < 0.05 vs. matched EBC, blood or pulmonary parenchyma.
c p < 0.05 vs. matched EBC and blood.
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patients with lower stage (1.61  0.20 vs. 1.30  0.28,
p Z 0.004) and similarly, in central vs. peripheral location
(1.50  0.21 vs. 1.23  0.29, p < 0.001). NSCLC histology
(squamous cell cancer vs. other types) did not affect R
mut/wild KRAS (1.39  0.26 vs. 1.33  0.31, p Z 0.49).
Sequence analysis of KRAS oncogene at codon 12
revealed the following point mutations: ggt / gct
(n Z 44), ggt / gat (n Z 8) and ggt / gtt (n Z 5) with
similar distribution in NSCLC (35:7:4) and BL (9:1:1),
respectively.
Sixteen of 57 samples of normal pulmonary parenchyma
(13 from NSCLC and 3 from BL patients) revealed
mutated KRAS oncogene. R mut/wild KRAS of pulmonaryFigure 2 Effect of surgical resection of benign pulmonary
lesion (BL, n Z 11) and non small cell lung cancer (NSCLC,
n Z 46) on exhalation of mutated KRAS oncogene. Results
(mean and standard deviation) are expressed as the ratio of
mutated to wild KRAS oncogene in DNA extracted from exhaled
breath condensate (EBC R mut/wild KRAS) collected within 3
days before surgery (open bar), and 7 (dotted bar) and 30 days
(closed bar) after complete tumor resection. * - EBC R mut/
wild KRAS: before surgery vs. at 7th day and at 7th day vs. at
30th day, significantly different at p < 0.001 (Wilcoxon test) # -
EBC R mut/wild KRAS before surgery: BL vs. NSCLC, signifi-
cantly different at p < 0.05 (Wilcoxon test).parenchyma in patients with NSCLC and BL was 68- and 109-
times lower (p < 0.001) than that of corresponding tumors
(Table 2).
Effect of tumor resection on KRAS mutations in EBC
Complete tumor resection resulted in significant decline of
EBC R mut/wild KRAS in all patients. In NSCLC patients
mean EBC R mut/wild KRAS at the 7th and 30th day after
surgery was 1.3- and 3.7-times lower (p < 0.001) than that
before treatment (Fig. 2). Ten NSCLC patients had no
detectable KRAS mutations in EBC at 30th day after surgery.
In patients with BL, EBC R mut/wild KRAS decreased by
1.2- and 2.7-times (p < 0.001) at 7th and 30th day after
resection and was undetectable in 2 patients at the last
time-point.
Correlations between measured variables
EBC R mut/wild KRAS before surgery did not correlate with
blood and tumor R mut/wild KRAS in the all patients with
pulmonary tumor and separately, in NSCLC group (Table 3).
Similar results were noted for correlation between these
variables in subgroups of NSCLC patients with central
(n Z 22) and peripheral (n Z 24) location of cancerTable 3 Correlations (r value) between the ratio of
mutant to wild KRAS oncogene (R mut/wild KRAS) in pre-
surgery exhaled breath condensate (EBC) and peripheral
blood and resected tumor in the whole group of patients
with pulmonary lesions and in the patients with NSCLC.
Variable Ratio of mutant to wild KRAS
oncogene in EBC-DNA
Whole group,
n Z 57
NSCLC patients,
n Z 46
Tumor R
mut/wild KRAS
0.00 0.20
Blood R
mut/wild KRAS
0.00 0.16
The whole group involved 46 NSCLC patients and 11 patients
with benign lesions; p > 0.05 for all calculated r.
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respectively). EBC R mut/wild KRAS at the day 7th and 30th
after surgery did not correlate with blood and pulmonary
parenchyma R mut/wild KRAS in NSCLC patients (data not
shown). Similarly, there were no associations between
tumor and blood R mut/wild KRAS (rZ 0.09) or cumulative
cigarette consumption (r Z 0.14). EBC R mut/wild KRAS
(before and at 7th and 30th day after surgery) did not
correlate with patients stage (data not shown). There was
also no association between decline of EBC R mut/wild
KRAS during 30 days after cancer resection and patients
stage (r Z 0.03, p > 0.05).Discussion
We analyzed the effect of surgical treatment on exhalation
of mutated KRAS oncogene in the group of patients with
clinical diagnosis of lung cancer, positive for KRAS mutation
at codon 12 in EBC-DNA. We found that complete resection
of pulmonary cancer or benign lesion resulted in significant
decrease of EBC R mut/wild KRAS over one month obser-
vation. It suggests that resected lesion was the source of
extra-cellular DNA bearing KRAS mutations in EBC which is
supported by the following observations: (A) all excised
lesions had KRAS mutations at codon 12; (B) the majority of
normal pulmonary parenchyma specimens had no such
mutations, (C) mean EBC R mut/wild KRAS was higher than
that observed in specimens of pulmonary parenchyma.
DNA can be released from cells due to apoptosis,
necrosis or spontaneous active release processes.27,28 It can
be found in human plasma, airways epithelial lining fluid
(ELF), sputum and EBC.6,7,12,17,19,27,28 Lung cancer patients
had increased concentrations of free circulating DNA27,28
and partly, this DNA originated from the tumor cells.29
Thus, cell-free DNA can be a surrogate for analysis of
genomic alterations.27,28
We expected that complete tumor resection would yield
negative EBC specimens for KRAS mutation over one month
of observation. However, only 12 of 57 EBC specimens
become negative 30 days after surgery. It cannot be
excluded that circulating DNA molecules can diffuse from
pulmonary microvasculature into ELF leading to KRAS
positive EBC after surgery. However, the lack of correlation
between pre-surgery EBC and pre-surgery blood R mut/wild
KRAS rather excludes such possibility.
A part of pulmonary parenchyma specimens disclosed
mutated KRAS oncogene suggesting the presence of this
mutations in uninvolved regions of the lungs. This is in
accordance with previous reports30,31 and suggests, that
DNA released from pulmonary parenchyma cells could
contribute to some extent to positive results after cancer
resection. However, no correlation between EBC and
pulmonary parenchyma R mut/wild KRAS also excludes this
possibility.
The occurrence of KRAS positive EBC after complete
tumor resection could be the result of relatively long half
time of extra-cellular DNA bearing KRAS mutations in ELF.
Majority of DNA released from cells does not exist as a free
molecules in body fluids.27 It can bind via specific proteins
to the outer membrane of cells (e.g. erythrocytes, leuko-
cytes).32 It is possible that DNA released from pulmonarylesions can adhere to airways epithelium and be gradually
released from its surface to ELF after tumor resection.
Further, EBC can contain inflammatory and epithelial cells
with extra-cellular DNA attached to the outer membrane.11
These may explain the occurrence of positive results
(despite significant reduction of R mut/wild KRAS) in
majority of EBC specimens collected 30 days after
complete tumor resection. Moreover, these could also
explain why pre-surgery EBC R mut/wild KRAS did not
correlate with blood and tumor R mut/wild KRAS. Binding of
extra-cellular DNA bearing KRAS mutations to airways cells
can act as a buffer slowing down changes of the DNA
content in ELF and subsequently in EBC. This hypothesis can
be supported by the observation of similar pre-surgery EBC
R mut/wild KRAS in NSCLC patients subgroups with various
cancer stage.
Eleven patients with nonmalignant lesions had KRAS
mutations in EBC, blood and specimen of excised tumor. It
agrees with previous studies showing KRAS mutations in BAL
obtained from patients with nonmalignant pulmonary
lesions (focal fibrosis, pneumonia)33 and indicates that
KRAS mutation in EBC is not specific.
Relatively high proportion of patients with squamous cell
carcinoma to patients with adenocarcinoma (22e17) is
quite surprising, since KRAS mutations were found to occur
3- to 4-times more frequently in adenocarcinoma than in
squamous cell carcinoma.15 However, in our study the main
inclusion criterion was the presence of KRAS mutations at
codon 12 in EBC-DNA. Cancer histology and its KRAS muta-
tion status were determined subsequently after surgery.
EBC reflects the changes in airways lining fluid and thus
could be similar to some extent to sputum and bronchial
washings.8 The amount of free DNA in airways lining fluid
may depend on the intensity of concomitant inflammatory
response34 and the exfoliation of cancer cells with their
subsequent disintegration that is more intense in squamous
cancer than in adenocarcinoma.35,36 These may explain the
high proportion of squamous cell carcinoma patients in the
studied group.
On the other hand, our results are in agreement with
those reported by Kersting and coworkers who found similar
ratio of KRAS mutations in patients with adenocarcinoma
and squamous cell carcinoma based on sputum analysis.37
Half of control subjects without any lung pathology had
KRAS mutations in EBC-DNA. All of them were current ciga-
rette smokers and this agrees with observation that the
number of microsatellite DNA alterations in EBC was directly
related to tobacco consumption in healthy subjects.10
This is in contrast with recent reports showing no KRAS
mutations in sputum samples obtained from cigarette
smokers without any lung pathology.18,38 In these studies
DNA electroforegrams were analyzed traditionally while in
our study we calculated EBC R mut/wild KRAS using Image
Master VDS that amplifies many-times the sensitivity of DNA
detection.26 KRAS mutations were found in 15% of lung
adenocarcinomas obtained from patients who had never
smoked cigarettes.39 This suggests that cigarette smoking is
not a necessary condition for induction of KRAS mutation in
the respiratory tract. On the other hand, further studies are
necessary to determine whether EBC R mut/wild KRAS
around 0.002 found in cigarette smokers can have any
clinical or predictive significance.
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crude specimens of pulmonary tumor that could be
contaminated to variable extent with unaffected pulmo-
nary tissue. Assuming that KRAS mutations are mainly
present in pathological cells the contamination with normal
tissue would result in lower R mut/wild KRAS. Moreover,
this could also explain lack of reciprocal correlations
between R mut/wild KRAS in tumor, blood and EBC before
surgery.
The second limitation of our study was the restriction of
the KRAS mutation sequence analysis to DNA from speci-
mens of resected pulmonary lesions. Previous report on
KRAS mutations in excised NSCLC and paired serum that
involved 51 patients showed higher ratio of positive results
in plasma than in tumor and only one patient carried the
same mutation in both specimens.40 The existence of other
extra-tumor sources of KRAS mutations (e.g. damaged
hematopoietic cells)41 and the intra-tumor heterogeneity
of KRAS mutations can be responsible for the above
described discrepancy. Different specimens of the same
tumor (e.g. prostate carcinoma, colorectal carcinoma)
revealed different mutations of the KRAS oncogene and p53
tumor suppressor gene.42,43 This phenomenon can occur
also in lung cancer and as neoplastic cell clones with
different mutations or without them can release various
amounts of DNA into blood or ELF.44 Since in our study, only
one specimen of excised tumor was analyzed, the
phenomenon of intratumor heterogeneity regarding muta-
tional status can be an additional factor explaining no
associations between R mut/wild KRAS in pre-surgery EBC,
blood and tumor tissue.
Nevertheless, complete resection of lung cancer resul-
ted in decreased exhalation of mutated KRAS oncogene and
some patients became negative for KRAS mutation in EBC-
DNA 30 days after surgery.
On the other hand, majority of operated lung cancer
patients were still positive for KRAS mutation in EBC-DNA
over one month of observation. In addition, EBC mutated
KRAS oncogene was also found in patients with benign
pulmonary lesion that presented similar decline of EBC R
mut/wild KRAS in response to complete surgical resec-
tion. Moreover, more than 50% of screened patients with
lung tumor were negative for KRAS mutation. These
indicate rather low specificity and sensitivity of EBC R
mut/wild KRAS as a single genetic marker of lung cancer.
However, it cannot be excluded that determination of
EBC R mut/wild KRAS in combination with other genetic
markers could be useful in follow-up after surgical
treatment as a potential marker of the recurrence of
pulmonary malignancy. Therefore, further, long-term
clinical studies monitoring genomic alterations in post-
surgery EBC-DNA with reference to patient’s clinical
status and survival are necessary for evaluation of this
hypothesis and selection of valuable genetic marker(s) of
pulmonary malignancy.Acknowledgments
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